ME03802B - Rezim doziranja agonista s1p receptora - Google Patents
Rezim doziranja agonista s1p receptoraInfo
- Publication number
- ME03802B ME03802B MEP-2020-156A MEP2020156A ME03802B ME 03802 B ME03802 B ME 03802B ME P2020156 A MEP2020156 A ME P2020156A ME 03802 B ME03802 B ME 03802B
- Authority
- ME
- Montenegro
- Prior art keywords
- dose
- receptor
- agonist
- product
- use according
- Prior art date
Links
- 229940044601 receptor agonist Drugs 0.000 title claims 9
- 239000000018 receptor agonist Substances 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 14
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 14
- 239000000556 agonist Substances 0.000 claims 9
- 229940075993 receptor modulator Drugs 0.000 claims 8
- 238000011287 therapeutic dose Methods 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 6
- 238000011283 initial treatment period Methods 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 238000000159 protein binding assay Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Upotreba modulatora ili agonista S1P receptora u proizvodnji leka za lečenje autoimunske bolesti, pri čemu je autoimunska bolest izabrana sa liste koja se sastoji od multiple skleroze, polimiozitisa, lupus nefritisa, reumatoidnog artritisa, zapaljenske bolesti creva i psorijaze, pri čemu se, pre otpočinjanja primene modulatora ili agonista SIP receptora u standardnoj dnevnoj terapijskoj dozi, navedeni modulator ili agonist S1P receptora primenjuje u dnevnoj dozi koja je niža od standardne dnevne terapijske doze tokom početnog perioda lečenja i pri čemu je najviša početna doza izmedu 0,01 mg i 0,30 mg.
2. Modulator ili agonist S1P receptora za upotrebu u lečenju autoimunske bolesti, pri čemu je autoimunska bolest izabrana sa liste koja se sastoji od multiple skleroze, polimiozitisa, lupus nefritisa, reumatoidnog artritisa, zapaljenske bolesti creva i psorijaze, pri čemu se, pre otpočinjanja primene modulatora ili agonista S1P receptora u standardnoj dnevnoj terapijskoj dozi, navedeni modulator ili agonist S1P receptora primenjuje u dnevnoj dozi koja je niža od standardne dnevne terapijske doze tokom početnog perioda lečenja i pri čemu je najviša početna doza izmedu 0,01 mg i 0,30 mg.
3. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačeni time što početni period lečenja je izabran iz grupe koja se sastoji od:do 10 dana i 5 do 14 dana.
4. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačeni time što se ista doza daje u toku prvih 2 do 4 dana lečenja pre povećanja doze.
5. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačeni time što se ista doza daje u toku prvih 4 dana lečenja pre povećanja doze.
6. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačeni time što u poetnom periodu lečenja dnevna doza je povećavana postepeno do 6 puta do standardne dnevne terapijske doze i zatim se lečenje nastavlja sa standardnom terapijskomdnevnom dozom.
7. Upotreba ili proizvod za upotrebu prema bilo kom od patentnih zahteva 1-8, naznačeni time što se tokom početnog perioda lečenja javlja samo jedno povećanje doze pre davanja standardne dnevne terapijske doze.
8. Upotreba ili proizvod za upotrebu prema bilo kom od patentnih zahteva 1-8, naznačeni time to je u toku početnog perioda lečenja doza povećana samo jednom da bi se dostigla standardna dnevna terapijska doza.
9. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačeni time što je modulator ili agonist S1P receptora selektivan za S1P1receptor.
10. Upotreba ili proizvod za upotrebu prema patentnom zahtevu 9, naznačeni time što modulator ili agonist S1P receptora poseduje selektivnost za S1P1 receptor u odnosu na S1P3 receptor od najmanje 20, 100, 500, 1000 ili 2000 puta više, kao to je mereno preko odnosa EC50 za S1P1receptor prema EC50 za S1P3 receptor kao to je mereno preko analize vezivanja 35S-GTPγS i pri čemu navedeni modulator ili agonist S1P receptora ima EC50 za vezivanje za S1P1 receptor od 100 nM ili manje kao to je procenjivano preko analize vezivanja 35S-GTPγS.
11. Upotreba ili proizvod za upotrebu prema bilo kom od prethodnih patentnih zahteva, naznačen time, bolest je multipla skleroza.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13967208P | 2008-12-22 | 2008-12-22 | |
| US21853009P | 2009-06-19 | 2009-06-19 | |
| US24671509P | 2009-09-29 | 2009-09-29 | |
| EP18201062.9A EP3453387B1 (en) | 2008-12-22 | 2009-12-21 | Dosage regimen for a s1p receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03802B true ME03802B (me) | 2021-04-20 |
Family
ID=41667217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-156A ME03802B (me) | 2008-12-22 | 2009-12-21 | Rezim doziranja agonista s1p receptora |
| MEP-2019-339A ME03594B (me) | 2008-12-22 | 2009-12-21 | Režim doziranja agonista s1p receptora |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-339A ME03594B (me) | 2008-12-22 | 2009-12-21 | Režim doziranja agonista s1p receptora |
Country Status (43)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009115954A1 (en) * | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| PL2379067T3 (pl) | 2008-12-22 | 2016-02-29 | Novartis Ag | Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego |
| EP3061449A1 (en) | 2009-09-29 | 2016-08-31 | Novartis AG | Dosage regimen of an s1p receptor modulator |
| US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
| CA2786994C (en) | 2010-01-27 | 2018-01-16 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| AU2011249789B2 (en) * | 2010-05-06 | 2015-03-19 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
| JP6111202B2 (ja) | 2011-01-07 | 2017-04-05 | ノバルティス アーゲー | 免疫抑制製剤 |
| US9592288B2 (en) | 2011-02-18 | 2017-03-14 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| WO2012162392A1 (en) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
| TW201320994A (zh) * | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
| SMT202000298T1 (it) | 2012-08-17 | 2020-07-08 | Actelion Pharmaceuticals Ltd | Processo per la produzione di (2z,5z)-5-(3-cloro-4((r)-2,3-diidrossipropossi) benziliden)-2-(propilimmino)-3-(o-tolil)tiazolidin-4-one e intermedio usato in detto processo |
| US20160129084A1 (en) * | 2013-03-06 | 2016-05-12 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure |
| US10022340B2 (en) | 2013-10-11 | 2018-07-17 | Teikoku Pharma Usa, Inc. | Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same |
| US10675254B2 (en) | 2013-10-11 | 2020-06-09 | Teikoku Seiyaku Co., Ltd. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| EP3831378A1 (en) * | 2014-04-10 | 2021-06-09 | Novartis AG | Siponimod immediate release dosage regimen for treating autoimmune diseases |
| DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| TW202131921A (zh) | 2019-10-31 | 2021-09-01 | 瑞士商愛杜西亞製藥有限公司 | Cxcr7拮抗劑與s1p1受體調節劑之組合 |
| WO2021158838A1 (en) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
| WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
| EP4110332A4 (en) * | 2020-02-28 | 2024-03-06 | Akaal Pharma Pty Ltd | S1p receptor modulators |
| CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| AU8533101A (en) | 2000-08-31 | 2002-03-13 | Merck & Co Inc | Phosphate derivatives as immunoregulatory agents |
| CA2483594C (en) | 2002-05-16 | 2011-02-15 | Novartis Ag | Use of edg receptor binding agents in cancer |
| US20050090520A1 (en) * | 2003-09-12 | 2005-04-28 | Per Lindquist | Treatment of disease or injury of the nervous system with FTY720 |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| SG187468A1 (en) * | 2004-11-29 | 2013-02-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| CN101541227B (zh) * | 2005-02-10 | 2013-06-05 | G.I.视频有限公司 | 用于带导向元件的胃肠工具的前进技术 |
| PT2465492E (pt) * | 2007-10-12 | 2015-10-15 | Novartis Ag | Composições que compreendem moduladores de receptores de esfingosina-1-fosfato (s1p) |
| WO2009115954A1 (en) * | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
| KR20180017232A (ko) * | 2008-06-20 | 2018-02-20 | 노파르티스 아게 | 다발성 경화증을 치료하기 위한 소아용 조성물 |
| PL2379067T3 (pl) | 2008-12-22 | 2016-02-29 | Novartis Ag | Schemat dawkowania fingolimodu w leczeniu stwardnienia rozsianego |
| WO2010072703A1 (en) | 2008-12-22 | 2010-07-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
-
2009
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 SM SM20200441T patent/SMT202000441T1/it unknown
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en not_active Revoked
- 2009-12-21 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 ES ES22187007T patent/ES3017254T3/es active Active
- 2009-12-21 EP EP22187007.4A patent/EP4098256B9/en active Active
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 SM SM20200054T patent/SMT202000054T1/it unknown
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 PT PT221870074T patent/PT4098256T/pt unknown
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 MX MX2018006099A patent/MX385959B/es unknown
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en not_active Ceased
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 LT LTEP22187007.4T patent/LT4098256T/lt unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en not_active Revoked
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 HR HRP20250568TT patent/HRP20250568T1/hr unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 HU HUE22187007A patent/HUE071189T2/hu unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active Active
- 2009-12-21 RS RS20250452A patent/RS66784B9/sr unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 SI SI200932211T patent/SI4098256T1/sl unknown
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 PL PL22187007.4T patent/PL4098256T3/pl unknown
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 FI FIEP22187007.4T patent/FI4098256T3/fi active
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 DK DK22187007.4T patent/DK4098256T5/da active
-
2011
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en not_active Abandoned
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092377A patent/JP2024129030A/ja active Pending
- 2024-09-27 US US18/900,154 patent/US20250262171A1/en active Pending
-
2025
- 2025-04-08 FR FR25C1012C patent/FR25C1012I1/fr active Active
- 2025-04-11 CY CY2025012C patent/CY2025012I2/el unknown
- 2025-05-19 LT LTPA2025520C patent/LTPA2025520I1/lt unknown
- 2025-05-23 FI FIC20253002C patent/FIC20253002I1/fi unknown
- 2025-06-13 HU HUS2500026C patent/HUS2500026I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201167T1 (hr) | Režim doziranja agonista s1p receptora | |
| ME03780B (me) | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze | |
| Pascual-Brazo et al. | Modulation of neuroplasticity pathways and antidepressant-like behavioural responses following the short-term (3 and 7 days) administration of the 5-HT4 receptor agonist RS67333 | |
| AR134222A2 (es) | Un proceso para preparar una composición de comprimido adecuada para el tratamiento de trastornos mediados por la actividad de la tirosina cinasa de bruton | |
| Vulink et al. | Sexual pleasure in women with obsessive-compulsive disorder? | |
| SI2501234T1 (en) | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine | |
| MX2009003098A (es) | Compuestos de tiofen pirazolopirimidina. | |
| Wang et al. | Mechanisms of mechanical force in periodontal homeostasis: A review | |
| MY146388A (en) | Thiazole pyrazolopyrimidines as crfi receptor antagonists | |
| ES2525497T3 (es) | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico | |
| BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
| MX336663B (es) | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada. | |
| WO2007147090A3 (en) | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity | |
| WO2006052723A3 (en) | G protein coupled receptor agonists and antagonists and methods of use | |
| MY156822A (en) | Indole derivatives as s1p1 receptor agonists | |
| HRP20110206T1 (hr) | Derivati 3-(heteroaril-oksi)-2-alkil-1-aza-bicikloalkila kao alfa.7-nachr liganda za liječenje cns bolesti | |
| ME01916B (me) | Novi spoj koristan u liječenju degenerativnih upalnih bolesti | |
| CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
| Halaris et al. | The glutamatergic system in treatment-resistant depression and comparative effectiveness of ketamine and esketamine: role of inflammation? | |
| BR112013001299A2 (pt) | composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano | |
| NZ599315A (en) | Antibody therapeutics with local activity in the digestive tract | |
| CL2007002975A1 (es) | Composicion farmaceutica de liberacion modificada que comprende microesferas recubiertas con un farmaco musculo relajante y un farmaco aine; proceso de preparacion y uso en el tratamiento de espasticidad, desordenes relacionados con padecimientos musculares y/o musculo esqueleticos. | |
| JP2012522788A5 (me) | ||
| WO2010123959A3 (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| CU24528B1 (es) | Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina |